派林生物：子公司人凝血酶注册临床试验申请获受理

Core Viewpoint - The company announced that its wholly-owned subsidiary, Guangdong Shuanglin Biopharmaceutical Co., Ltd., has received the acceptance notice for the clinical trial registration of human thrombin from the National Medical Products Administration [1] Group 1: Regulatory Approval - The National Medical Products Administration has reviewed and accepted the drug registration application based on Article 32 of the Administrative Licensing Law of the People's Republic of China [1] - The human thrombin is indicated for external use only, aimed at controlling minor bleeding from capillaries and small veins when standard surgical techniques are ineffective or impractical [1] Group 2: Product Usage - The product can be used in conjunction with absorbable gelatin sponges for enhanced hemostatic effect [1]